Basic Information
| LncRNA/CircRNA Name | PCAT14 |
| Synonyms | PCAT14 |
| Region | GRCh38_22:23536881-23547797 |
| Ensemble | ENSG00000280623 |
| Refseq | NR_109832 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | RNA-seq, qPCR, RNAi, ISH etc. |
| Sample | prostate cancer tissues, cell lines (VCaP, LNCa) |
| Expression Pattern | up-regulated |
| Function Description | An RNA in-situ hybridization (ISH) assay for PCAT14 distinguished benign vs malignant cases, as well as high vs low Gleason disease. PCAT14 is transcriptionally regulated by AR, and endogenous PCAT14 overexpression suppresses cell invasion. Thus, Using RNA-sequencing data we identify PCAT14, a novel prostate cancer and lineage-specific lncRNA. PCAT14 is highly expressed in low grade disease and loss of PCAT14 predicts for disease aggressiveness and recurrence. |
| Pubmed ID | 27566105 |
| Year | 2016 |
| Title | Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. |
External Links
| Links for PCAT14 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |